Human B7-2 Fc Recombinant Protein, PeproTech | Invitrogen 310-33-20UG product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

protein

product name :

Human B7-2 Fc Recombinant Protein, PeproTech

catalog :

310-33-20UG

quantity :

20 ug

price :

US 93.50

product information

Product Type :

Protein

Product Name :

Human B7-2 Fc Recombinant Protein, PeproTech

Catalog # :

310-33-20UG

Quantity :

20 ug

Price :

US 93.50

Clonality :

Recombinant

Purity :

purified

Reactivity :

Human

Applications :

Functional Assay: Assay-dependent

Species :

Human

Storage :

-20 C

Description :

CD86 is one of two ligands (the other CD80) for CTLA4 and CD28. CD86 acts as costimulatory molecule in eliciting T-cell help during antigen presentation. Antigen presentation in the absence of sufficient co-stimulation involving CD86/CD80 can induce tolerance. CD80 appears to play a role distinct from CD80 in T helper cell differentiation. CD86 is a type I membrane protein that is a member of the immunoglobulin superfamily. The CD86 protein is expressed by antigen-presenting cells, and it is the ligand for two proteins at the cell surface of T cells, CD28 antigen and cytotoxic T-lymphocyte-associated protein 4. Binding of CD86 with CD28 antigen is a costimulatory signal for activation of the T-cell. Binding of CD86 with cytotoxic T-lymphocyte-associated protein 4 negatively regulates T-cell activation and diminishes the immune response. Alternative splicing results in two transcript variants encoding different isoforms of CD86. Additional transcript variants have been described for CD86, but their full-length sequences have not been determined. Diseases associated with CD86 dysfunction include gallbladder squamous cell carcinoma and myocarditis.

Format :

Lyophilized

Applications w/Dilutions :

Functional Assay: Assay-dependent

Aliases :

activation B7-2 antigen; B lymphocyte activation antigen B72; B7; B7.2; B70; B7-2; B-lymphocyte activation antigen B7-2; BU63; CD28 antigen ligand 2; Cd28l2; CD28LG2; CD86; CD86 antigen; CD86 antigen (CD28 antigen ligand 2, B7-2 antigen); CD86 antigen precursor; CD86 molecule; CLS1; CTLA-4 counter-receptor B7.2; early T cell costimulatory molecule-1; early T-cell costimulatory molecule 1; Early T-cell co-stimulatory molecule 1; ETC-1; FUN-1; LAB72; Ly58; Ly-58; MB7; MB7-2; membrane glycoprotein; MGC34413; T-lymphocyte activation antigen CD86; TS/A-2